The Delta
What changed in your universe.
18 thesis deltas since your last session. Ranked by materiality, confidence movement and source quality across the 30-day window.
18
New deltas
3
Critical
7
Red Team
142
Sources
Today's analyst queue
3 same-day alerts · FDA compounding action, CMS pricing signal
7 evidence gaps · payer coverage, channel persistence require corroboration
8 weekly brief candidates · demand proxies, competitor pipeline updates
Priority Delta
Regulatory
FDA 503B proposal detected: semaglutide, tirzepatide, liraglutide compounding exclusion. Reduces 503B compounding overhang but branded demand recapture uncertain.
Impact: Updates Execution & Supply pillar. Compounding risk thread moved to active monitoring. Channel substitution via 503A workarounds and patient churn unresolved.
Open Situation Room · Monitor comment period · Track Rx proxies
Pricing
CMS GLP-1 Bridge page updated. Medicare drug price negotiation includes Ozempic, Rybelsus and Wegovy. Net price anchor emerging.
Impact: Updates Access & Pricing pillars. Creates model sensitivity task for volume vs net price trade-off. Broader access possible but restriction language matters.
View pricing thread · Create sensitivity analysis
Competitor
Survodutide (Zealand/Boehringer) Phase III obesity data reported positive. Next-gen dual agonist adds differentiation pressure to incumbents.
Impact: Updates Competition pillar. Raises competitor pressure confidence. Incumbents retain scale advantage but pipeline diversification accelerates.
View competitor matrix · Compare vs Zepbound/Wegovy
Situation Room
5 strategic questions.
The GLP-1 investment debate structured as hypothesis threads — confidence movement, evidence gaps and decision triggers across 142 sources in the last 30 days.
Are GLP-1 obesity leaders still mispriced because the market underestimates long-duration volume expansion, or are consensus estimates too aggressive?
04
Situation Room
Confidence Up
Are net price assumptions for Novo/Lilly vulnerable to Medicare, commercial payer, PBM, or employer pressure that consensus models have not yet repriced?
68%
Confidence
High
Materiality
6 src
Evidence
Red Team: Do not upgrade bull thesis confidence until the source chain separates CMS access expansion from actual net-price compression. Volume gains are meaningless if gross-to-net deterioration offsets them.
Critical · Updated today
FDA compounding proposal: one event, two thesis impacts. Compounding overhang reduced, but branded demand recapture remains unresolved.
Vextrum separates what is known from what is assumed. The FDA action reduces one bear objection, but the investment conclusion depends on channel dynamics that the proposal does not address.
↓ 503B compounding overhang: reduced
↓ Channel substitution risk: declining
? Branded Rx recapture rate: uncertain
= 503A workaround risk: unresolved
Bull interpretation
FDA enforcement on 503B compounders removes the largest channel-leakage risk. Branded Rx demand recaptures volume, supporting Novo/Lilly revenue trajectory into 2027.
Bear interpretation
503A compounding workarounds, telehealth channel persistence, and patient cost sensitivity will limit branded recapture. Revenue quality improvement smaller than bulls assume.
Open full proof path: source event → extracted claim → entity mapping → thesis decomposition → Red Team → analyst task → PM brief.
2 days ago
FDA 503B proposal published: semaglutide, tirzepatide, liraglutide added to compounding exclusion list.
Wire
5 days ago
Telehealth platform commentary indicates continued 503A compounding demand despite FDA signaling.
Extended
2 weeks ago
Novo Nordisk Q1 earnings: management commentary on gross-to-net trajectory and Medicare exposure extracted.
Wire
Blind Spots
Where we lack evidence.
Coverage gaps against your strategic questions. User-defined from onboarding and agent-detected from monitoring silence.
Gap
Employer-Level GLP-1 Coverage Data
Large employer benefit design changes for GLP-1 obesity coverage. Bull thesis H1 assumes employer adoption is accelerating, but evidence is insufficient to validate.
Request source discovery runAdd manual dataEscalate to weekly brief
Partial
Patient Persistence and Discontinuation Rates
Real-world persistence data beyond 12 months for obesity GLP-1s. Long-duration volume expansion is core to bull thesis — without persistence evidence, demand projections are assumption-heavy.
Upgrade source tierCreate analyst task
Gap
Oral GLP-1 Pricing and Payer Strategy
Oral semaglutide and orforglipron pricing signals, payer formulary positioning. Oral formulations could expand TAM or compress injectable economics — both scenarios affect thesis materially.
Add to source discoveryEscalate to weekly brief
Competitive
Competitive Position Analysis
Who is gaining or losing strategic advantage, and what does it mean for my thesis or position?
| Company | Position | Pipeline | Obesity % | Oral/Next-Gen | Time to Mkt | Diff. Risk | Threat |
|---|---|---|---|---|---|---|---|
| Novo Nordisk | Leader | High | ~65% | Phase III | Now | Low | 85% |
| Eli Lilly | Leader | High | ~30% | Early | Now | Low | 82% |
| Zealand / BI | Challenger | Med | ~80% | No | 2028+ | Med | 49% |
| Amgen | Entrant | Med | ~60% | No | 2028+ | Med | 42% |
| Viking | Early | Low | ~90% | Phase II | 2029+ | Low | 28% |
Competitor SignalMateriality: Medium
Survodutide Phase III positive obesity data increases long-term competition pressure but immediate materiality limited by commercial timing.
Red Team: Reduce immediate materiality — commercial timing 2+ years, label path uncertain, no US commercial partner confirmed. Efficacy differentiation is promising but not displacement-ready.
Build competitor matrixView trial dataCompare efficacy/tolerability
3 days ago · Med confidence
Amgen MariTide Phase II dosing data suggests monthly SC injection advantage vs weekly tirzepatide. Differentiation angle: convenience.
1 week ago · Early stage
Viking VK2735 oral formulation enters Phase II. Oral + injectable dual development strategy observed.
2 weeks ago · High confidence
Novo/Lilly combined obesity market share proxies stable at ~85%. No immediate competitive displacement detected.
Investment
What Should You Do Now?
Thesis position, conviction gates, and the evidence that would change your mind.
Thesis Position
Bull favoured · 66% vs 45%
3 unresolved gates
GLP-1 obesity leaders remain underpriced by consensus — but conviction requires 3 evidence gates before upgrading.
Bull thesis leads on demand and access evidence. Bear thesis weakening on compounding overhang. However, net-price compression, channel persistence, and employer coverage data are unresolved. Do not increase position size until at least 2 of 3 gates clear.
Gate 1 — Unresolved
Net price after Medicare negotiation
CMS anchor emerging, but actual gross-to-net impact on Novo 2027 guidance unknown. Wait for Q2 commentary.
Track CMS updates
Gate 2 — Unresolved
Branded Rx recapture after 503B
503B overhang reduced, but channel migration to branded not yet visible in Rx data. Need 2-3 months of IQVIA/Symphony data.
Monitor Rx proxies
Gate 3 — Partial
Employer coverage = real access?
Headlines say "employer adoption accelerating" but PA requirements may block conversion. Need employer-level utilization data, not just formulary additions.
Request source discovery
66%↑4
Bull Thesis
Demand + access evidence strengthening. Click to see 8 supporting signals
45%↓3
Bear Thesis
Compounding overhang declining. Click to see 5 weakening factors
61%↑4
Access Risk
CMS anchor + PA barriers rising. Click to see 4 risk signals
70%↑2
Pricing Pressure
Medicare negotiated pricing. Click to see net-price analysis
49%↑7
Competition Risk
Survodutide Phase III positive. Click to see competitor pipeline
52%↓3
Execution/Channel
Supply normalizing, FDA 503B helps. Click to see channel data
| Entity | Exposure | Direction | Materiality | Evidence | Your Action |
|---|---|---|---|---|---|
| Novo Nordisk | High | Pricing ↓ | Critical | Strong | Wait for Q2 GTN guidance |
| Eli Lilly | High | Demand ↑ | Critical | Strong | Demand thesis holding — monitor supply |
| CVS / Caremark | Medium | Formulary shift | High | Moderate | Track PA language changes |
| UnitedHealth / Optum | Medium | Coverage expand | High | Partial | Evidence gap — employer data needed |
| Express Scripts | Medium | PBM strategy | Medium | Weak | No signal — monitoring |
Red Team: Do not upgrade revenue confidence until channel migration or branded prescription evidence appears. Sentiment is not revenue. Volume expansion headlines require net-price validation. Decision trigger: If Gate 1 + Gate 2 clear within 60 days, bull thesis upgrades to >75% conviction.
Expansion
Market & Indication Expansion
Where is the addressable market growing, and are expansion assumptions realistic?
Expansion Vector
Evidence
Timing
Affected
Conf.
Missing
Obesity coverage expansion
Strong
Now
NVO, LLY
72%
Employer-level data
Medicare Part D pathway
Moderate
2027
NVO
61%
Restriction language
Cardiovascular label
Moderate
2026-27
NVO, LLY
65%
Outcomes data
MASH / CKD indications
Early
2027+
LLY
38%
Trial readouts
Oral GLP-1 formulations
Early
2027+
NVO, LLY, PFE
44%
Pricing strategy
State Medicaid expansion
Partial
Varies
All
40%
State-level decisions
1. Nominal coverage does not equal real access — PA, step edits, BMI thresholds may block conversion to reimbursed demand.
2. Employer adoption headlines may overstate actual lives covered. Most large employers add with PA requirements.
3. Supply constraints may cap revenue even if access improves. Lilly capacity limited through 2026.
4. Oral GLP-1 may expand TAM but compress per-patient economics. Mix dilution risk unresolved.
5. International reimbursement timelines are assumption-heavy. EU HTA decisions fragmented and uncertain.
Executive
Management Commentary & Leadership
Is management or leadership behavior changing the interpretation of the thesis?
| Company | Source | Quote / Paraphrase | Topic | Sentiment | Confirms? |
|---|---|---|---|---|---|
| Novo Nordisk | Q1 2026 | "Supply normalization on track for H2 2026" | Supply | Constructive | Yes |
| Novo Nordisk | Q1 2026 | "Gross-to-net pressure manageable within guidance range" | Pricing | Cautious | Partially |
| Eli Lilly | Inv Day | "Zepbound demand exceeds manufacturing capacity through 2026" | Demand | Bullish | Yes |
| Eli Lilly | Q1 2026 | "Employer coverage additions accelerating but with PA requirements" | Access | Mixed | Partially |
SupplyPrevious: "constrained"→New: "normalizing"
Supports bull execution thesis. Consistent with manufacturing capex commentary.
PricingPrevious: "confident in pricing power"→New: "manageable within range"
Slightly softer tone. Watch for gross-to-net compression language in Q2.
1 week ago
Novo Nordisk CFO commentary on Medicare exposure at healthcare conference. Characterized negotiated pricing as "manageable" but provided no quantitative guidance.
2 weeks ago
Lilly manufacturing VP promoted to EVP with expanded scope including new API plant. Signals accelerated capacity commitment.
Regulatory
Policy & Access Rules
What regulatory, policy or payer actions are changing the risk/opportunity landscape?
Critical · ProposedPolicy: PROPOSED
FDA proposes semaglutide/tirzepatide/liraglutide exclusion from 503B bulks list
Red Team: Proposed, not finalized — comment period may weaken enforcement. Do not upgrade revenue confidence until channel migration evidence appears.
Monitor comment periodTrack 503A workaroundsUpdate compounding thread
2 days ago
FDA 503B proposal published
Proposed
Critical
1 week ago
CMS GLP-1 Bridge page updated
Effective
High
2 weeks ago
PBM formulary PA language flagged
Monitoring
Medium
3 weeks ago
State Medicaid DUR committee GLP-1 review scheduled
Upcoming
Medium
1 month ago
ICER obesity treatment value assessment draft
Draft
High
Payer
PA Req
Step Edit
BMI
Qty Limit
Reauth
Trend
Medicare Part D
Yes
No
≥30 / 27+
30 day
6 month
Expanding
UnitedHealthcare
Yes
Yes
≥30
30 day
12 month
Stable
Express Scripts
Yes
No
≥30 / 27+
90 day
6 month
Loosening
Employer Plans
Varies
Common
27-35
Varies
Varies
Mixed
1. FDA proposal is proposed, not finalized — comment period may weaken enforcement scope.
2. CMS coverage does not equal physician prescribing. Real-world uptake may lag policy by 6-12 months.
3. State Medicaid expansion is budget-dependent and politically variable.
4. PBM access rules change quarterly — current snapshot may not reflect H2 2026 reality.
Living Knowledge
Thesis Graph, Not Document Storage
The living memory of the GLP-1 intelligence universe. Every entity, relationship, and evidence snippet is linked to a hypothesis, a debate pillar, and an analyst action.
Company
Drug/Product
Clinical Trial
Payer/Access
Regulatory
Hypothesis
Click a node to inspect · Double-click to expand
Click a node to inspect entity details, relationships, and evidence.
Example Path
FDA 503B Proposal
→ affects compounded semaglutide/tirzepatide
→ updates Compounding Risk signal
→ supports Bull Hypothesis H4
→ creates Analyst Task: monitor channel
→ updates Situation Room Thread #1
126
Entities
312
Relationships
87
Evidence Snippets
18
Hypothesis Links
11
Contradictions
9
Analyst Tasks